Not trading or investment advice, but you would think that any buyer of SRX today gets a free option on the possibility that good R&D news is announced prior to market open on Monday.
Worst case is that no substantive developments are announced, in which case it is back to business as usual and waiting for the trial results in H1 2017.
Not trading or investment advice, but you would think that any...
Add to My Watchlist
What is My Watchlist?